Not all triple-negative breast cancers are the same, with certain subtypes being more aggressive than others, according to a study.
Adding Lynparza to standard treatment for early-stage HER2-negative breast cancer with a high risk of recurrence in people with a BRCA1 or BRCA2 mutation improved disease-free survival.
People taking hormonal therapy medicine to treat breast or prostate cancer have a higher risk of heart attack and stroke as they get older and should be monitored regularly to detect any problems.
Skipping sentinel lymph node biopsy and/or radiation therapy didn’t affect recurrence rates or survival for women age 70 and older diagnosed with early-stage, hormone-receptor-positive, HER2-negative, clinically node-negative breast cancer.
Black women who are diagnosed with triple-negative breast cancer are 28% more likely to die from the disease than white women with the same diagnosis.
Receiving 3 to 5 years of bisphosphonate treatment after surgery and chemotherapy for early-stage breast cancer doesn’t improve survival any more than receiving 2 years of bisphosphonate treatment.
Black women diagnosed with breast cancer who also have central obesity — excess body fat in the abdominal area — were more likely to die from breast cancer or any other cause than similar women who didn’t have central obesity.
Adding Tukysa to the standard of care of Herceptin and Xeloda continued to improve both progression-free and overall survival in people diagnosed with either metastatic or unresectable locally advanced HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla.
About 86% of women diagnosed with metastatic breast cancer had at least one bad treatment-related side effect, and 92% were willing to discuss options for different dosing levels of medicines based on their unique situations.
People diagnosed with breast cancer who got an ultralow risk of recurrence score on the MammaPrint genomic test had excellent long-term outcomes, whether or not they received hormonal therapy and/or chemotherapy after surgery.
Women who report worse quality of life factors, such as poor physical well-being, poor social well-being, and a history of depression, are more likely to stop hormonal therapy early.
Compared to standard chemotherapy, Trodelvy offered better outcomes for people diagnosed with previously treated metastatic triple-negative breast cancer.
Results from two studies on using the immunotherapy medicines Tecentriq or Keytruda along with chemotherapy to treat early-stage triple-negative breast cancer before surgery suggested that Keytruda offered benefits while Tecentriq did not.
About 65% of women diagnosed with breast cancer don't meet national exercise recommendations after they've been diagnosed, and Black women are much less likely to meet exercise recommendations than white women.
Electroacupuncture ‚Äì a type of acupuncture where a small electric current passes between pairs of acupuncture needles ‚Äì has been found to ease fatigue, anxiety, and depression in women diagnosed with early-stage breast cancer who are taking an aromatase inhibitor.
Early results suggest that treating just the area around where a cancer used to be with radiation may be as good as treating the whole breast with radiation.
Hypofractionated radiation after lumpectomy offers better quality of life than conventional schedule.
A study suggests that women 67 and older diagnosed with early-stage breast cancer are more satisfied cosmetically with lumpectomy and brachytherapy compared to other treatment options.
A study has found that women older than 80 diagnosed with early-stage, hormone-receptor-negative breast cancer don't get survival benefits from chemotherapy.
Non-white women have more severe pain with advanced breast cancer than white women.
The combination of Taxotere (chemical name: docetaxel) and Cytoxan (chemical name: cyclophosphamide) offers better survival and fewer and less severe side effects than the combination of Adriamycin (chemical name: doxorubicin) and Cytoxan for treating breast cancer.
Removing the ovaries and taking tamoxifen after breast cancer surgery had benefits for premenopausal women shows a new study done in Vietnam and China.
A new study shows that women who smoked and got radiation therapy to treat breast cancer had a much higher risk of lung cancer later on compared to women who got radiation and didn't smoke.
While most women having breast cancer surgery won't develop an infection, research shows that infections after breast surgery happen more often than expected.